Sirtex Renews Grant to Support Vanderbilt's RESIN Registry of Y-90 Microspheres to Treat Liver Tumors
April 18, 2018—Vanderbilt University in Nashville, Tennessee, recently announced that Sirtex Medical Inc. has renewed a grant awarded to Daniel B. Brown, MD, and his Vanderbilt Health colleagues, for a research program designed to treat patients with liver tumors that cannot be addressed with surgery. The research agreement renewal from Sirtex will provide $2.64 million over 3 years to support a patient registry. Combined with the original contract, reimbursement to Vanderbilt totals more than $3 million.
Sirtex designed the SIR-Spheres yttrium-90 (Y-90) radioactive isotope resin microspheres that lodge in the microvasculature surrounding a tumor where 94% of the radiation inside the spheres is delivered to the tumor within 11 days.
In 2015, Dr. Brown and colleagues launched the Radiation-Emitting Selective Internal Radiation-Spheres in Non-Resectable (RESIN) liver tumor registry. Dr. Brown, who has served as the Principal Investigator of the registry, is Professor of Radiology and Radiological Sciences and Chief of Interventional Oncology at Vanderbilt. The Vanderbilt-Ingram Cancer Center is the sponsor of the registry.
According to the Vanderbilt press release, the RESIN registry tracks cancer patients whose tumors are treated with the SIR-Spheres. The current study includes both academic and private groups with the goal of collecting real-world data about the use of this device for primary and metastatic liver cancer. The registry includes tumor type, prescribed activity of radiation, and any chemotherapy or immunotherapy drugs given. It also includes a number of cell receptors that are treated with targeted therapies.
In comments to Endovascular Today, Dr. Brown noted that 999 patients have been enrolled to date at 40 medical centers. The registry's goal is to enroll 3,000 patients. "I am indebted to my Chair, Reed Omary, MD, and to Jennifer Pietenpol, PhD, Director of the Vanderbilt-Ingram Cancer Center, for their support in developing and maintaining this novel study," said Dr. Brown to Endovascular Today.
In Vanderbilt's announcement, Dr. Brown commented, “The updated contract will expedite the collection and review of patient data and will allow further development of the database, which will smooth out data entry and mining. This evolution of the study will enhance our abilities to publish as our data matures. We are looking to evaluate real-world usage to identify potential combinations of Y90 and immunotherapy or chemotherapy that can be studied prospectively to improve patient care.
"This updated agreement with Sirtex shows their commitment to this research project, which will be the largest of its kind in the interventional radiology space at its conclusion. I would like to thank Sirtex Medical as well as the support staff here at Vanderbilt University Medical Center: Ursula Halmon, Catherine Gregor, Kristin Surdam, and Jennifer Baker.”